Michael Alexander Smith net worth and biography

Michael Smith Biography and Net Worth

Michael Alexander Smith is the Sr. VP & Gen. Counsel at Insmed Inc.

What is Michael Alexander Smith's net worth?: The estimated net worth of Michael Alexander Smith is at least $2.23 million as of January 9th, 2024. Mr. Smith owns 86,364 shares of Insmed stock worth more than $2,229,055 as of April 25th. This net worth approximation does not reflect any other assets that Mr. Smith may own. Learn More about Michael Alexander Smith's net worth.
How do I contact Michael Alexander Smith?: The corporate mailing address for Mr. Smith and other Insmed executives is 700 US Highway 202/206, Bridgewater NJ, 08807. Insmed can also be reached via phone at 908-977-9900 and via email at [email protected]. Learn More on Michael Alexander Smith's contact information.
Has Michael Alexander Smith been buying or selling shares of Insmed?: Michael Alexander Smith has not been actively trading shares of Insmed in the last ninety days. Most recently, Michael Alexander Smith sold 2,373 shares of the business's stock in a transaction on Tuesday, January 9th. The shares were sold at an average price of $28.76, for a transaction totalling $68,247.48. Following the completion of the sale, the vice president now directly owns 86,364 shares of the company's stock, valued at $2,483,828.64. Learn More on Michael Alexander Smith's trading history.
Who are Insmed's active insiders?: Insmed's insider roster includes Roger Adsett (COO), Sara Bonstein (CFO), David Brennan (Director), Martina Flammer (Insider), William Lewis (CEO), Orlov Nicole Schaeffer (Insider), Melvin Sharoky (Director), Michael Smith (VP), and John Wise (Insider). Learn More on Insmed's active insiders.
Are insiders buying or selling shares of Insmed?: In the last year, insiders at the biopharmaceutical company sold shares 18 times. They sold a total of 271,590 shares worth more than $7,211,082.98. The most recent insider tranaction occured on January, 12th when insider Martina M.D. Flammer sold 4,667 shares worth more than $133,616.21. Insiders at Insmed own 4.6% of the company. Learn More about insider trades at Insmed.
Information on this page was last updated on 1/12/2024.

Michael Alexander Smith Insider Trading History at Insmed

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
1/9/2024	Sell	2,373	$28.76	$68,247.48	86,364
1/5/2024	Sell	627	$29.30	$18,371.10	88,737
7/11/2023	Sell	740	$20.18	$14,933.20	77,142
1/10/2023	Sell	1,836	$17.93	$32,919.48	54,332
1/5/2023	Sell	720	$19.72	$14,198.40	49,836
7/12/2022	Sell	941	$23.40	$22,019.40	50,455
1/11/2022	Sell	407	$25.11	$10,219.77
1/5/2022	Sell	749	$27.61	$20,679.89

Michael Alexander Smith Buying and Selling Activity at Insmed

Insmed Company Overview

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. MAC lung disease is a rare and often chronic infection that can cause irreversible lung damage and can be fatal. Insmed's earlier-stage clinical pipeline includes INS1007, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases, and INS1009, an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for rare pulmonary disorders, including pulmonary arterial hypertension.

Today's Range

Now: $25.81

$25.38

$25.96

50 Day Range

MA: $27.24

$24.11

$29.51

2 Week Range

Now: $25.81

$18.08

$32.00

Volume

2,740,799 shs

Average Volume

1,780,172 shs

Market Capitalization

$3.83 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.92

Global crypto currency reset (41 major banks signed up)

From Stansberry Research | Ad

Behind closed doors, at least 41 major US banks have signed up to a strange new crypto project...

Here's everything you need to know.